Clínica Oftalmológica do Complexo Hospitalar Padre Bento de Guarulhos, Guarulhos, São Paulo, Brazil.
Indian J Ophthalmol. 2022 Aug;70(8):3134-3136. doi: 10.4103/ijo.IJO_1021_22.
This report shows a case of corneal transplant rejection after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), short after receiving the BNT162b2 vaccine, in a patient who had undergone keratoplasty more than 20 years ago, with no previous episodes of rejection and no other factor that could lead to the findings on his examinations. After treatment with high doses of topic, oral, and sub-conjunctival corticoids, the patient had a favorable therapeutic response. The signs of corneal transplant rejection must be oriented to the patients and the causing factors actively searched by ophthalmologists so that treatment is rapidly initiated and sequels are avoided. This report raises the question if these events are correlated and whether the patient should receive the second dose of the vaccine against SARS-CoV-2 or not.
本报告介绍了一例 20 多年前接受角膜移植术且无排斥反应病史的患者,在接种 BNT162b2 疫苗后不久发生了与严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫苗接种相关的角膜移植排斥反应。在经过高剂量局部、口服和结膜下皮质类固醇治疗后,患者的治疗反应良好。角膜移植排斥反应的体征必须引起患者和眼科医生的重视,并积极寻找病因,以便迅速开始治疗并避免后遗症。本报告提出了一个问题,即这些事件是否相关,以及患者是否应该接种第二剂 SARS-CoV-2 疫苗。